相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: A translational link to humans
Joanna C. Neill et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2014)
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
Adam J. Pawson et al.
NUCLEIC ACIDS RESEARCH (2014)
Antipsychotic Induced Weight Gain: Genetics, Epigenetics, and Biomarkers Reviewed
Tahireh A. Shams et al.
CURRENT PSYCHIATRY REPORTS (2014)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: LIGAND-GATED ION CHANNELS
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: ENZYMES
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: ION CHANNELS
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation
D. Bolognini et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: G PROTEIN-COUPLED RECEPTORS
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Improving the Treatment of Schizophrenia: Role of 5-HT Receptors in Modulating Cognitive and Extrapyramidal Motor Functions
Saki Shimizu et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2013)
The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity
E. T. Wargent et al.
NUTRITION & DIABETES (2013)
Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation
L. De Petrocellis et al.
ACTA PHYSIOLOGICA (2012)
Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus
E. M. Rock et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Serotonin Receptors as Targets for Drugs Useful to Treat Psychosis and Cognitive Impairment in Schizophrenia
H. Y. Meltzer et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2012)
Modulation of L-α-Lysophosphatidylinositol/GPR55 Mitogen-activated Protein Kinase (MAPK) Signaling by Cannabinoids
Sharon Anavi-Goffer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
GENDER-DEPENDENT BEHAVIORAL AND BIOCHEMICAL EFFECTS OF ADOLESCENT DELTA-9-TETRAHYDROCANNABINOL IN ADULT MATERNALLY DEPRIVED RATS
E. Zamberletti et al.
NEUROSCIENCE (2012)
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes
Luciano De Petrocellis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Therapeutic Role of 5-HT1A Receptors in The Treatment of Schizophrenia and Parkinson's Disease
Yukihiro Ohno
CNS NEUROSCIENCE & THERAPEUTICS (2011)
Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine
Cinzia Guidali et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2011)
Chronic URB597 treatment at adulthood reverted most depressive-like symptoms induced by adolescent exposure to THC in female rats
N. Realini et al.
NEUROPHARMACOLOGY (2011)
AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents
Mark D. Black et al.
PSYCHOPHARMACOLOGY (2011)
Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews
Erin M. Rock et al.
PSYCHOPHARMACOLOGY (2011)
Evidence that the plant cannabinoid cannabigerol is a highly potent alpha(2)-adrenoceptor agonist and moderately potent 5HT(1A) receptor antagonist
M. G. Cascio et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
The plant cannabinoid Δ9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice
Daniele Bolognini et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
J. C. McGrath et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Carol Kilkenny et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats
Alexandre Seillier et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Depression-like phenotype following chronic CB1 receptor antagonism
Chad E. Beyer et al.
NEUROBIOLOGY OF DISEASE (2010)
SLV330, a cannabinoid CB1 receptor antagonist, ameliorates deficits in the T-maze, object recognition and Social Recognition Tasks in rodents
N. M. W. J. de Bruin et al.
NEUROBIOLOGY OF LEARNING AND MEMORY (2010)
Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801 Clz and MK-801 in KO1A mice
Maria Cecilia Scorza et al.
NEUROPHARMACOLOGY (2010)
Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism
Joanna C. Neill et al.
PHARMACOLOGY & THERAPEUTICS (2010)
Subchronic Effects of Phencyclidine on Dopamine and Serotonin Receptors: Implications for Schizophrenia
Yong Kee Choi et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2009)
Allosteric modulation of 5-HT1A receptors by zinc: Binding studies
Sergio Barrondo et al.
NEUROPHARMACOLOGY (2009)
Improvement of phencyclidine-induced social behaviour deficits in rats:: Involvement of 5-HT1A receptors
Shikha Snigdha et al.
BEHAVIOURAL BRAIN RESEARCH (2008)
Effects of Δ9-tetrahydrocannabivarin on [35S] GTPγS binding in mouse brain cerebellum and piriform cortex membranes
I. Dennis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta(9)-tetrahydrocannabinol, cannabidiol and Delta(9)-tetrahydrocannabivarin
R. G. Pertwee
BRITISH JOURNAL OF PHARMACOLOGY (2008)
The phytocannabinoid Δ9-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum
Y-L Ma et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Models of schizophrenia in humans and animals based on inhibition of NMDA receptors
Vera Bubenikova-Valesova et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2008)
The CB1 cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus
Gunnar Thiemann et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2008)
Risperidone and ritanserin but not haloperidol block effect of dizocilpine on the active allothetic place avoidance task
Vera Bubenikova-Valesova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The psychoactive plant cannabinoid, Delta(9)-tetrahydrocannabinol, is antagonized by Delta(8)- and Delta(9)-tetrahydrocannabivarin in mice in vivo
R. G. Pertwee et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
Charles H. Large
JOURNAL OF PSYCHOPHARMACOLOGY (2007)
F15063, a compound with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties:: (III) Activity in models of cognition and negative symptoms
R. Depoortere et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine
Merce Amargos-Bosch et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2006)
Evidence that the plant cannabinoid Δ9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist
A Thomas et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Effects of novel antipsychotics with mixed D2 antagonist/5-HT1A agonist properties on PCP-induced social interaction deficits in the rat
LAB Slot et al.
NEUROPHARMACOLOGY (2005)
Allosteric modulation of the cannabinoid CB1 receptor
MR Price et al.
MOLECULAR PHARMACOLOGY (2005)
Agonistic properties of cannabidiol at 5-HT1a receptors
EB Russo et al.
NEUROCHEMICAL RESEARCH (2005)
Novel antipsychotic agents with 5-HT1A agonist properties:: Role of 5-HT1A receptor activation in attenuation of catalepsy induction in rats
MS Kleven et al.
NEUROPHARMACOLOGY (2005)
Inverse agonism and neutral antagonism at cannabinoid CBI receptors
RG Pertwee
LIFE SCIENCES (2005)
Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat
RS Martin et al.
PSYCHOPHARMACOLOGY (2003)
Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex
BW Adams et al.
BIOLOGICAL PSYCHIATRY (2001)
The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?
RA Bantick et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2001)
分享论文
